RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目的总体目标是通过使用放射性标记的单克隆抗体（放射免疫疗法，RIT）向靶淋巴造血组织提供补充辐射，改善非霍奇金淋巴瘤和急性白血病患者的干细胞移植结局。靶向方法的改进可能允许从抗体向白血病和淋巴瘤细胞递送更大剂量的放射性，同时向正常器官递送更低的辐射剂量，从而导致更高的治愈率和更少的治疗相关毒性。这些非人灵长类动物研究的具体目的是： a.评价放射性标记生物素化抗体给药后在猕猴中进行体外吸附的可行性、安全性和毒性。 B.评估体外吸附治疗（ECAT）对放射性标记生物素化抗体在猕猴中的药代动力学和生物分布的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this project is to improve the outcome of stem cell transplantation for patients with non-Hodgkin's lymphoma and acute leukemia by delivering supplemental radiation to target lymphohematopoietic tissues using radiolabeled monoclonal antibodies (radioimmunotherapy, RIT). The improvement of targeting methods may allow the delivery of larger doses of radioactivity from antibody to leukemia and lymphoma cells, while delivering lower radiation doses to normal organs, resulting in higher cure rates and less treatment-related toxicity. The specific aims in these non-human primate studies are: a. To evaluate the feasibility, safety, and toxicity of administering radiolabeled-biotinylated antibodies followed by extracorporeal adsorption in macaques. b. To assess the impact of extracorporeal adsorption therapy (ECAT) on the pharmacokinetics and biodistribution of radiolabeled-biotinylated antibodies in macaques.